Healthcare & Bio Medical Devices
NS01-20LF
20ml
Orange
By forming a physical antimicrobial film on the nasal mucosa, it helps relieve rhinitis symptoms and
-
Buy Sample
LUCA V-Defense Nasal Spray is a nasal spray medical device that protects against respiratory viral infections. Many countries that have suffered from the coronavirus pandemic have recently lifted the mandatory wearing of masks. LUCA V-Defense Nasal Spray is a minimal safety device that can prevent respiratory viral infections instead of masks. When V-Defense containing antibacterial lipid and lambda carrageenan is applied to the nasal and nasal mucosa, a physical antibacterial film is formed to prevent the penetration of viruses.
The capacity is 20mL, equivalent to about 200 uses, and the nasal mucosa is coated with an antibacterial agent by putting spray nozzles in both nasal passages and spraying them once each. The coating maintenance time is about 4 to 5 hours, and it is recommended to use it 3 times a day normally.
Various safety, stability, and efficacy tests have been completed, and KGMP, ISO13485, CE MDR, USA FDA, Spanish AEMPS, Thailand FDA and Singapore HSA, Malaysia, Philippines, Vietnam certifications have been obtained. Currently, we are exporting to USA, Thailand, and they are sold through local pharmacies, Shopee, LAZADA, etc. As a result of the COVID-19 virus test at Mahidol University, a professional certification body in Thailand, 99.7% antiviral performance was confirmed within 1 minute.
Category | Main Item |
---|---|
|
|
CEO | SeungHee Ahn |
---|---|
Foundation Year | - |
Annual sales(per year) | Less than 1 million dollar |
Employees | Under 50 |
Homepage | http://www.lucaaicell.com |
Address | (14055) 경기 안양시 동안구 시민대로327번길 11-35, 3층 |
Company Introduction | LUCA AICell Inc. is a bio-platform company that utilizes the core technology of nanotechnology-based artificial cell membranes (lipid bilayers) to develop new technologies such as a drug delivery system, virus and cancer (CTC) diagnostics, drug screening and development platforms, and a gene delivery platform. Namjoon Cho, the chief technology officer of LUCA AICell, Inc. and a chair professor of materials engineering at Nanyang Technological University in Singapore, is a world-class authority in artificial cell membranes. He has written about 270 papers related to Lipids for about 20 years. He has excellent technology enough to be listed 10 times in Nature and 30 selected as representative papers of the month in top journals. Business areas are Drug Delivery System (DDS, drug delivery system), Anti-viral Peptides (antiviral treatment), and LNP Applications (LNP grafting business). In recognition of its outstanding technological prowess, LUCA AICell received $4 million in funding from the National Institutes of Health (NIH) in the United States. And LUCA AICell recently attracted an investment of KRW 5 billion from KDB Development Bank for the first time as a bio company. |